A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.

Authors:

Abstract
TPS4161 Background: Approximately 5% of unselected pancreatic cancer (PC) patients (pts), 10% of PC pts of Ashkenazi Jewish descent, and up to 19% of familial PC families, harbor a germline BRCA mutation. PARP inhibitors (PARPi) have exhibited clinical activity in pts with a BRCA mutation. Rucaparib, an oral PARPi, is being developed for treatment of cancers associated with homologous recombination repair (HRR) deficiency due to a BRCA mutation or other HRR pathway defect. Rucaparib has demonstrated clinical activity (RECIST and CA-125 responses) in pts with BRCAmut pancreatic, ovarian, or breast cancer in an ongoing Phase 1/2 study (NCT01482715). Clinical activity of PARPi in BRCAmut PC combined with the paucity of active 2nd-line therapies support evaluation of rucaparib in PC pts with a deleterious BRCA mutation. Methods: Study CO-338-023 (NCT02042378) is a single-arm, open-label Phase 2 trial of continuous rucaparib in up to 100 pts with pancreatic ductal adenocarcinoma (or related subtype) and a know...